Mumbai: The farmers in Maharashtra, who are undertaking a rally with demands related to onion prices, called off their protest on Saturday.

Further details are awaited.

Let the Truth be known. If you read VB and like VB, please be a VB Supporter and Help us deliver the Truth to one and all.



New Delhi: A recent study conducted by Sankha Shubhra Chakrabarti and his team at Banaras Hindu University has shed light on adverse events observed in participants who received Covaxin, Bharat Biotech's COVID-19 vaccine.

The study involved 1,024 individuals, comprising 635 adolescents and 291 adults, who were followed up for one year after receiving Covaxin.

Nearly a third of the participants reported adverse events of special interest (AESI) during the observation period. These included viral upper respiratory tract infections, new-onset skin and subcutaneous disorders, general disorders, nervous system disorders, menstrual abnormalities in females, ocular abnormalities, and hypothyroidism.

The study identified several risk factors associated with AESI. Female adolescents and individuals with a history of allergies were found to be at higher risk. Additionally, participants with pre-vaccination COVID-19, comorbidities, and post-vaccination typhoid were also identified as having increased risk.

A significant number of AESIs persisted even at the 1-year follow-up. Female individuals, adolescents with pre-vaccination COVID-19, those with comorbidities, and those with post-vaccination typhoid had higher odds of persistent AESIs.

Among serious adverse events, stroke and Guillain-Barre Syndrome were identified in a small percentage of participants.

The study highlights the importance of extended surveillance of COVID-19 vaccinated individuals to understand the course and outcomes of late-onset adverse events. Focused monitoring for persistent AESIs is recommended, especially for individuals with certain risk factors.

The findings suggest that the patterns of adverse events observed with Covaxin differ from those reported with other COVID-19 vaccines. Understanding these patterns is crucial for effective post-vaccination monitoring and management of potential risks.